Antiviral activity of gliotoxin, gentian violet and brilliant green against Nipah and Hendra virus in vitro

Virology Journal

Volumn 6, Issue , 2009, Pages

  Aljofan, Mohamad ^a,d   Sganga, Michael L ^b   Lo, Michael K ^c   Rootes, Christina L ^a   Porotto, Matteo ^b   Meyer, Adam G ^a   Saubern, Simon ^a   Moscona, Anne ^b   Mungall, Bruce A ^a,b  

^a CSIRO   (Australia)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BRILLIANT GREEN; CRYSTAL VIOLET; DISINFECTANT AGENT; GLIOTOXIN; INTERLEUKIN 8; MESSENGER RNA; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL CELL; ANTIBODY LABELING; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; GENE EXPRESSION; HENDRA VIRUS; HUMAN; HUMAN CELL; IC 50; INFLUENZA VIRUS A; MONOLAYER CULTURE; NIPAH VIRUS; NONHUMAN; PARAINFLUENZA VIRUS 3; PROTEIN EXPRESSION; PSEUDOTYPING; REAL TIME POLYMERASE CHAIN REACTION; RNA VIRUS INFECTION; VESICULAR STOMATITIS VIRUS; ANIMAL; CERCOPITHECUS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; VERO CELL; VIRUS GENOME;

BACTERIA (MICROORGANISMS); FRASERA; GENTIANA; HENDRA VIRUS; HUMAN PARAINFLUENZA VIRUS 3; INFLUENZA A VIRUS; NIPAH VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DRUG EVALUATION, PRECLINICAL; GENOME, VIRAL; GENTIAN VIOLET; GLIOTOXIN; HENDRA VIRUS; MOLECULAR STRUCTURE; NIPAH VIRUS; QUATERNARY AMMONIUM COMPOUNDS; VERO CELLS;

EID: 72949090228     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-6-187     Document Type: Article

References (76)

1. A morbillivirus that caused fatal disease in horses and humans. K Murray P Selleck P Hooper A Hyatt A Gould L Gleeson H Westbury L Hiley L Selvey B Rodwell, Science 1995 268 94 97 10.1126/science.7701348 7701348
2. Fatal encephalitis due to novel paramyxovirus transmitted from horses. JD O'Sullivan AM Allworth DL Paterson TM Snow R Boots LJ Gleeson AR Gould AD Hyatt J Bradfield, Lancet 1997 349 93 95 10.1016/S0140-6736(96)06162-4 8996421
3. Hendra virus, human, equine - Australia (04): (QLD). ProMed-mail, ProMed-mail 2008
4. Australian vet dies from Hendra virus infection. Anonymous, Vet Rec 2008 163 257
5. Hendra virus, human, equine - Australia (04): (Queensland) Fatal. ProMed-mail, ProMed-mail 2009
6. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia. KB Chua KJ Goh KT Wong A Kamarulzaman PS Tan TG Ksiazek SR Zaki G Paul SK Lam CT Tan, Lancet 1999 354 1257 1259 10.1016/S0140-6736(99)04299-3 10520635
7. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. KJ Goh CT Tan NK Chew PS Tan A Kamarulzaman SA Sarji KT Wong BJ Abdullah KB Chua SK Lam, N Engl J Med 2000 342 1229 1235 10.1056/ NEJM200004273421701 10781618
8. The natural history of Hendra and Nipah viruses. H Field P Young JM Yob J Mills L Hall J Mackenzie, Microbes Infect 2001 3 307 314 10.1016/S1286-4579(01) 01384-3 11334748
9. Fatal fruit bat virus sparks epidemics in southern Asia. D Butler, Nature 2004 429 7 10.1038/429007b 15129247
10. Emerging infectious diseases. Nipah virus (or a cousin) strikes again. M Enserink, Science 2004 303 1121 10.1126/science.303.5661.1121b 14976284
11. Nipah virus encephalitis reemergence, Bangladesh. VP Hsu MJ Hossain UD Parashar MM Ali TG Ksiazek I Kuzmin M Niezgoda C Rupprecht J Bresee RF Breiman, Emerg Infect Dis 2004 10 2082 2087 15663842
12. Person-to-person transmission of Nipah virus during outbreak in Faridpur District, 2004. B Icddr, Health and Science Bulletin 2004 2 2 5 9
13. Person-to-person transmission of Nipah virus in a Bangladeshi community. ES Gurley JM Montgomery MJ Hossain M Bell AK Azad MR Islam MA Molla DS Carroll TG Ksiazek PA Rota, et al. Emerg Infect Dis 2007 13 1031 1037 18214175
14. Evidence of Person-to-Person Transmission of Nipah Virus Through Casual Contact. N Homaira M Rahman MJ Hossain S Khatun N Nahar G Podder ES Gurley TG Ksiazek SP Luby, International Journal of Infectious Diseases 2008 12 Supplement 1 99 10.1016/j.ijid.2008.05.248
15. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. Z Zhu AS Dimitrov KN Bossart G Crameri KA Bishop V Choudhry BA Mungall YR Feng A Choudhary MY Zhang, et al. J Virol 2006 80 891 899 16378991 10.1128/JVI.80.2.891-899.2006 (Pubitemid 43062901)
16. Nipah virus: vaccination and passive protection studies in a hamster model. V Guillaume H Contamin P Loth MC Georges-Courbot A Lefeuvre P Marianneau KB Chua SK Lam R Buckland V Deubel TF Wild, J Virol 2004 78 834 840 14694115 10.1128/JVI.78.2.834-840.2004 (Pubitemid 38067605)
17. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. BA Mungall D Middleton G Crameri J Bingham K Halpin G Russell D Green J McEachern LI Pritchard BT Eaton, et al. J Virol 2006 80 12293 12302 17005664 10.1128/JVI.01619-06 (Pubitemid 44904379)
18. Efficacy of DNA immunization with F and G protein genes of Nipah virus. X Wang J Ge S Hu Q Wang Z Wen H Chen Z Bu, Ann N Y Acad Sci 2006 1081 243 245 10.1196/annals.1373.029 17135518
19. Recombinant nipah virus vaccines protect pigs against challenge. HM Weingartl Y Berhane JL Caswell S Loosmore JC Audonnet JA Roth M Czub, J Virol 2006 80 7929 7938 16873250 10.1128/JVI.00263-06 (Pubitemid 44182294)
20. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. KN Bossart G Crameri AS Dimitrov BA Mungall YR Feng JR Patch A Choudhary LF Wang BT Eaton CC Broder, J Virol 2005 79 6690 6702 15890907 10.1128/JVI.79.11.6690-6702.2005 (Pubitemid 40677300)
21. Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. KN Bossart BA Mungall G Crameri LF Wang BT Eaton CC Broder, Virol J 2005 2 57 16026621 10.1186/1743-422X-2-57 (Pubitemid 41321177)
22. Antibody prophylaxis and therapy against Nipah virus infection in hamsters. V Guillaume H Contamin P Loth I Grosjean MC Courbot V Deubel R Buckland TF Wild, J Virol 2006 80 1972 1978 16439553 10.1128/JVI.80.4.1972-1978. 2006 (Pubitemid 43228737)
23. Inhibition of Henipavirus infection by RNA interference. BA Mungall NC Schopman LS Lambeth TJ Doran, Antiviral Res 2008 80 324 331 10.1016/j.antiviral. 2008.07.004 18687361
24. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. M Porotto P Carta Y Deng GE Kellogg M Whitt M Lu BA Mungall A Moscona, J Virol 2007 81 10567 10574 17652384 10.1128/JVI.01181-07 (Pubitemid 47463330)
25. Inhibition of Hendra virus fusion. M Porotto L Doctor P Carta M Fornabaio O Greengard GE Kellogg A Moscona, J Virol 2006 80 9837 9849 16973588 10.1128/JVI.00736-06 (Pubitemid 44435658)
26. Recent progress in Henipavirus research. K Halpin BA Mungall, Comp Immunol Microbiol Infect Dis 2007 30 287 307 10.1016/j.cimid.2007.05.008 17629946
27. Treatment of acute Nipah encephalitis with ribavirin. HT Chong A Kamarulzaman CT Tan KJ Goh T Thayaparan SR Kunjapan NK Chew KB Chua SK Lam, Ann Neurol 2001 49 810 813 10.1002/ana.1062 11409437
28. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. L De Franceschi G Fattovich F Turrini K Ayi C Brugnara F Manzato F Noventa AM Stanzial P Solero R Corrocher, Hepatology 2000 31 997 1004 10.1053/he.2000.5789 10733558
29. RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR of RNA accumulation, the effect of ribavirin and the attenuation of transcription. PJ Wright G Crameri BT Eaton, Arch Virol 2005 150 521 532 10.1007/s00705-004-0417-5 15526144
30. Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. M Aljofan M Porotto A Moscona BA Mungall, J Virol Methods 2008 149 12 19 18313148 10.1016/j.jviromet.2008.01.016
31. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. MC Georges-Courbot H Contamin C Faure P Loth S Baize P Leyssen J Neyts V Deubel, Antimicrob Agents Chemother 2006 50 1768 1772 16641448 10.1128/AAC.50.5.1768-1772.2006
32. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. M Porotto G Orefice C Yokoyama B Mungall R Realubit M Sganga M Aljofan M Whitt F Glickman A Moscona, J Virol 2009 83 5148 5155 19264786 10.1128/JVI.00164-09
33. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J Pallister D Middleton G Crameri M Yamada R Klein TJ Hancock A Foord B Shiell W Michalski CC Broder LF Wang, J Virol 2009 19759137
34. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. OA Negrete EL Levroney HC Aguilar A Bertolotti-Ciarlet R Nazarian S Tajyar B Lee, Nature 2005 436 401 405 16007075
35. Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. OA Negrete MC Wolf HC Aguilar S Enterlein W Wang E Muhlberger SV Su A Bertolotti-Ciarlet R Flick B Lee, PLoS Pathog 2006 2 7 16477309 10.1371/journal.ppat.0020007
36. Development of a Neutralization Assay for Nipah Virus Using Pseudotype Particles. A Tamin BH Harcourt MK Lo JA Roth MC Wolf B Lee HM Weingartl JC Audonnet WJ Bellini PA Rota, J Virol Methods 2009 19559943
37. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. Y Kaku A Noguchi GA Marsh JA McEachern A Okutani K Hotta B Bazartseren S Fukushi CC Broder A Yamada, et al. J Virol Methods 2009 160 7 13 10.1016/j.jviromet.2009.04.037 19433112
38. Nipah virus conforms to the rule of six in a minigenome replication assay. K Halpin B Bankamp BH Harcourt WJ Bellini PA Rota, J Gen Virol 2004 85 701 707 10.1099/vir.0.19685-0 14993656
39. Characteristics of Nipah virus and Hendra virus replication in different cell-lines and their suitability for anti-viral screening. M Aljofan S Saubern AG Meyers G Marsh J Meers BA Mungall, Virus Res 2009 142 92 99 10.1016/j.virusres.2009.01.014 19428741
40. Dyes in dermatology. M Balabanova L Popova R Tchipeva, Clin Dermatol 2003 21 2 6 10.1016/S0738-081X(02)00330-9 12609582
41. The metabolism and mode of action of gentian violet. R Docampo SN Moreno, Drug Metab Rev 1990 22 161 178 10.3109/03602539009041083 2272286
42. Interactions during inhibition of growth of Aspergillus parasiticus by gentian violet. CL Hall PB Hamilton, Poult Sci 1981 60 2226 2231 7329907
43. Effect of dyes on bacterial growth. DY Fung RD Miller, Appl Microbiol 1973 25 793 799 4577179
44. The effect of cationic triphenylmethane dye (crystal violet) on rabbit granulation tissue. Oxygen consumption and RNA and protein synthesis in tissue slices. H Mobacken J Ahonen B Zederfeldt, Acta Derm Venereol 1974 54 343 347 4138232
45. Inhibition of protein synthesis and amino acid transport by crystal violet in Trypanosoma cruzi. ME Hoffmann J Jang SN Moreno R Docampo, J Eukaryot Microbiol 1995 42 293 297 10.1111/j.1550-7408.1995.tb01583.x 7496387
46. Inactivation of influenza A virus by gentian violet (GV) and GV-dyed cotton cloth, and bactericidal activities of these agents. A Nagayama, J Infect Chemother 2006 12 73 79 10.1007/s10156-005-0426-7 16648946
47. The membrane structure studied with cationic dyes. 1. The binding of cationic dyes to submitochondrial particles and the question of the polarity of the ion-translocation mechanism. P Dell'Antone R Colonna GF Azzone, Eur J Biochem 1972 24 553 565 10.1111/j.1432-1033.1972.tb19718.x 5058599
48. The response of cationic dyes to energy-linked changes of reconstituted mitochondrial membrane. L Frigeri A Bruni P Dell'Antone GF Azzone, FEBS Lett 1972 28 343 347 10.1016/0014-5793(72)80746-4 11946892
49. The effects of electrolytes on the interaction of cationic dyes with energized mitochondrial fragments. P Dell'Antone L Frigeri GF Azzone, Eur J Biochem 1973 34 448 454 10.1111/j.1432-1033.1973.tb02778.x 4715655
50. Interaction of certain cationic dyes with the respiratory chain of rat liver mitochondria. TE Conover RF Schneider, J Biol Chem 1981 256 402 408 7451446
51. Effect of inhibitors of electron transport and oxidative phosphorylation on Trypanosoma cruzi respiration and growth. AO Stoppani R Docampo JF de Boiso AC Frasch, Mol Biochem Parasitol 1980 2 3 21 10.1016/0166-6851(80)90044-4 7007881
52. Amphiphilic cationic drugs and phospholipids influence the activities of beta-galactosidase and beta-glucosidase from liver lysosomal fraction of untreated rats. A Harder G Dodt H Debuch, Biol Chem Hoppe Seyler 1985 366 189 193 2985099
53. Biphasic nature of the binding of cationic amphipaths with artificial and biological membranes. A Zachowski P Durand, Biochim Biophys Acta 1988 937 411 416 10.1016/0005-2736(88)90263-5 3337809
54. Effect of heat on the antimicrobial activity of brillant green dye. WA Moats JA Kinner SE Maddox Jr, Appl Microbiol 1974 27 844 847 4208510
55. Activity of gentian violet and brilliant green against some microorganisms associated with skin infections. P Bakker H Van Doorne V Gooskens NF Wieringa, Int J Dermatol 1992 31 210 213 10.1111/j.1365-4362.1992.tb03939.x 1568820
56. Determination of malachite green residues in the eggs, fry, and adult muscle tissue of rainbow trout (Oncorhynchus mykiss). JL Allen JE Gofus JR Meinertz, J AOAC Int 1994 77 553 557 8012199
57. Malachite green: a toxicological review. SJ Culp FA Beland, J Am Coll Toxicol 1996 15 219 238
58. Toxicological effects of malachite green. S Srivastava R Sinha D Roy, Aquat Toxicol 2004 66 319 329 10.1016/j.aquatox.2003.09.008 15129773
59. Carcinogenicity of malachite green chloride and leucomalachite green in B6C3F1 mice and F344 rats. SJ Culp PW Mellick RW Trotter KJ Greenlees RL Kodell FA Beland, Food Chem Toxicol 2006 44 1204 1212 10.1016/j.fct.2006.01.016 16554117
60. Enhancing effect of malachite green on the development of hepatic pre-neoplastic lesions induced by N-nitrosodiethylamine in rats. C Fernandes VS Lalitha KV Rao, Carcinogenesis 1991 12 839 845 10.1093/carcin/12.5.839 1674233
61. Teratological and other effects of malachite green on the development of rainbow trout and rabbits. FP Meyer TA Jorgensen, Trans Am Fish Soc 1983 112 818 824 10.1577/1548-8659(1983)112<818:TAOEOM2.0.CO;2
62. Inhibition of DNA synthesis in primary rat hepatocyte cultures by malachite green: a new liver tumor promoter. KV Rao, Toxicol Lett 1995 81 107 113 10.1016/0378-4274(95)03413-7 8553364
63. Antiseptic effect of a novel alcohol-free mouthwash: a convenient prophylactic alternative for high-risk patients. P Bahna HA Hanna T Dvorak A Vaporciyan M Chambers I Raad, Oral Oncol 2007 43 159 164 10.1016/j.oraloncology. 2006.02.002 16798063
64. Antiviral action of gliotoxin. JK McDougall, Arch Gesamte Virusforsch 1969 27 255 267 10.1007/BF01249648 4313024
65. Antiviral Activity of Gliotoxin and Gliotoxin Acetate. WA Rightsel HG Schneider BJ Sloan PR Graf FA Miller OR Bartz J Ehrlich GJ Dixon, Nature 1964 204 1333 1334 10.1038/2041333b0 14254440
66. Antiviral activity of gliotoxin. NM Larin MP Copping RH Herbst-Laier B Roberts RB Wenham, Chemotherapy 1965 10 12 23 10.1159/000220389 4285752
67. Specific inhibition of viral ribonucleic acid replication by Gliotoxin. PA Miller KP Milstrey PW Trown, Science 1968 159 431 432 10.1126/science.159. 3813.431 4294481
68. Gliotoxin: inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. PL Rodriguez L Carrasco, J Virol 1992 66 1971 1976 1372367
69. Inhibition of farnesyl-protein transferase by gliotoxin and acetylgliotoxin. D Van der Pyl J Inokoshi K Shiomi H Yang H Takeshima S Omura, J Antibiot (Tokyo) 1992 45 1802 1805 1281813
70. Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. DM Vigushin N Mirsaidi G Brooke C Sun P Pace L Inman CJ Moody RC Coombes, Med Oncol 2004 21 21 30 10.1385/MO:21:1:21 15034210
71. Sites of phosphorylation of P and V proteins from Hendra and Nipah viruses: newly emerged members of Paramyxoviridae. BJ Shiell DR Gardner G Crameri BT Eaton WP Michalski, Virus Res 2003 92 55 65 10.1016/S0168-1702(02) 00313-1 12606076
72. Ultrastructure of equine morbillivirus. AD Hyatt PW Selleck, Virus Res 1996 43 1 15 10.1016/0168-1702(96)01307-X 8822630
73. Simple method for estimating fifty percent end points. LJ Reed H Muench, Am J Hygiene 1938 27 493 497
74. A single amino acid alteration in the human parainfluenza virus type 3 hemagglutinin-neuraminidase glycoprotein confers resistance to the inhibitory effects of zanamivir on receptor binding and neuraminidase activity. MT Murrell M Porotto O Greengard N Poltoratskaia A Moscona, J Virol 2001 75 6310 6320 11413297 10.1128/JVI.75.14.6310-6320.2001 (Pubitemid 32578149)
75. Generation of henipavirus nucleocapsid proteins in yeast Saccharomyces cerevisiae. M Juozapaitis A Serva A Zvirbliene R Slibinskas J Staniulis K Sasnauskas BJ Shiell LF Wang WP Michalski, Virus Res 2007 124 95 102 10.1016/j.virusres.2006.10.008 17123657 (Pubitemid 46216564)
76. A system for functional analysis of Ebola virus glycoprotein. A Takada C Robison H Goto A Sanchez KG Murti MA Whitt Y Kawaoka, Proc Natl Acad Sci USA 1997 94 14764 14769 9405687 10.1073/pnas.94.26.14764 (Pubitemid 28041448)